cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.21688394
title: Supplementary Material for: Treatment of congenital hypothyroidism – impact of secular changes in levothyroxine initial dose on early growth

description: Introduction: Newborn screening of congenital hypothyroidism (CH) has enabled early treatment with levothyroxine (LT4), ensuring normal growth and development. The initial LT4 dose recommendation has increased over decades. We evaluated whether the increased LT4 dosing influenced thyroid-stimulating hormone (TSH) and thyroxine (fT4) concentrations, growth, or treatment-related symptoms. Methods: LT4 doses, TSH, fT4, anthropometrics, and treatment-related symptoms until age two years were evaluated in 172 Finnish CH patients born between 1980 and 2018. The patients were grouped according to birth decade: 1980s (n = 19, mean LT4 starting dose 6.8 µg/kg/day), 1990s (n = 50, 7.4 µg/kg/day), 2000s (n = 59, 9.7 µg/kg/day) and 2010s (n = 44, 10.8 µg/kg/day) Results: TSH concentrations were higher during the first two years of life in children born in 1980s compared to children born later. TSH concentrations were often subnormal in children receiving higher LT4 doses (children born in 2000s and 2010s). However, symptoms of overtreatment were uncommon. Linear or head growth showed no differences between the groups during the first two years of life. Although growth was within the normal spectrum, children in all groups were shorter than their target length at two years and their weight-for-length was above the mean through the first two years of life. Discussion/Conclusion: Current treatment practice with higher LT4 dose normalizes TSH rapidly without significant increase in side effects. However, irrespective of initial LT4 dose, children were shorter than expected at 2 years of age. Effects of different initial LT4 dose on cognitive development urges further investigation.
DOI: 10.6084/m9.figshare.21688394.v1
title: Supplementary Material for: Treatment of congenital hypothyroidism – impact of secular changes in levothyroxine initial dose on early growth

description: Introduction: Newborn screening of congenital hypothyroidism (CH) has enabled early treatment with levothyroxine (LT4), ensuring normal growth and development. The initial LT4 dose recommendation has increased over decades. We evaluated whether the increased LT4 dosing influenced thyroid-stimulating hormone (TSH) and thyroxine (fT4) concentrations, growth, or treatment-related symptoms. Methods: LT4 doses, TSH, fT4, anthropometrics, and treatment-related symptoms until age two years were evaluated in 172 Finnish CH patients born between 1980 and 2018. The patients were grouped according to birth decade: 1980s (n = 19, mean LT4 starting dose 6.8 µg/kg/day), 1990s (n = 50, 7.4 µg/kg/day), 2000s (n = 59, 9.7 µg/kg/day) and 2010s (n = 44, 10.8 µg/kg/day) Results: TSH concentrations were higher during the first two years of life in children born in 1980s compared to children born later. TSH concentrations were often subnormal in children receiving higher LT4 doses (children born in 2000s and 2010s). However, symptoms of overtreatment were uncommon. Linear or head growth showed no differences between the groups during the first two years of life. Although growth was within the normal spectrum, children in all groups were shorter than their target length at two years and their weight-for-length was above the mean through the first two years of life. Discussion/Conclusion: Current treatment practice with higher LT4 dose normalizes TSH rapidly without significant increase in side effects. However, irrespective of initial LT4 dose, children were shorter than expected at 2 years of age. Effects of different initial LT4 dose on cognitive development urges further investigation.
DOI: 10.6084/m9.figshare.21688397
title: Supplementary Material for: Treatment of congenital hypothyroidism – impact of secular changes in levothyroxine initial dose on early growth

description: Introduction: Newborn screening of congenital hypothyroidism (CH) has enabled early treatment with levothyroxine (LT4), ensuring normal growth and development. The initial LT4 dose recommendation has increased over decades. We evaluated whether the increased LT4 dosing influenced thyroid-stimulating hormone (TSH) and thyroxine (fT4) concentrations, growth, or treatment-related symptoms. Methods: LT4 doses, TSH, fT4, anthropometrics, and treatment-related symptoms until age two years were evaluated in 172 Finnish CH patients born between 1980 and 2018. The patients were grouped according to birth decade: 1980s (n = 19, mean LT4 starting dose 6.8 µg/kg/day), 1990s (n = 50, 7.4 µg/kg/day), 2000s (n = 59, 9.7 µg/kg/day) and 2010s (n = 44, 10.8 µg/kg/day) Results: TSH concentrations were higher during the first two years of life in children born in 1980s compared to children born later. TSH concentrations were often subnormal in children receiving higher LT4 doses (children born in 2000s and 2010s). However, symptoms of overtreatment were uncommon. Linear or head growth showed no differences between the groups during the first two years of life. Although growth was within the normal spectrum, children in all groups were shorter than their target length at two years and their weight-for-length was above the mean through the first two years of life. Discussion/Conclusion: Current treatment practice with higher LT4 dose normalizes TSH rapidly without significant increase in side effects. However, irrespective of initial LT4 dose, children were shorter than expected at 2 years of age. Effects of different initial LT4 dose on cognitive development urges further investigation.
DOI: 10.6084/m9.figshare.21688397.v1
title: Supplementary Material for: Treatment of congenital hypothyroidism – impact of secular changes in levothyroxine initial dose on early growth

description: Introduction: Newborn screening of congenital hypothyroidism (CH) has enabled early treatment with levothyroxine (LT4), ensuring normal growth and development. The initial LT4 dose recommendation has increased over decades. We evaluated whether the increased LT4 dosing influenced thyroid-stimulating hormone (TSH) and thyroxine (fT4) concentrations, growth, or treatment-related symptoms. Methods: LT4 doses, TSH, fT4, anthropometrics, and treatment-related symptoms until age two years were evaluated in 172 Finnish CH patients born between 1980 and 2018. The patients were grouped according to birth decade: 1980s (n = 19, mean LT4 starting dose 6.8 µg/kg/day), 1990s (n = 50, 7.4 µg/kg/day), 2000s (n = 59, 9.7 µg/kg/day) and 2010s (n = 44, 10.8 µg/kg/day) Results: TSH concentrations were higher during the first two years of life in children born in 1980s compared to children born later. TSH concentrations were often subnormal in children receiving higher LT4 doses (children born in 2000s and 2010s). However, symptoms of overtreatment were uncommon. Linear or head growth showed no differences between the groups during the first two years of life. Although growth was within the normal spectrum, children in all groups were shorter than their target length at two years and their weight-for-length was above the mean through the first two years of life. Discussion/Conclusion: Current treatment practice with higher LT4 dose normalizes TSH rapidly without significant increase in side effects. However, irrespective of initial LT4 dose, children were shorter than expected at 2 years of age. Effects of different initial LT4 dose on cognitive development urges further investigation.
DOI: 10.5281/zenodo.7351644
title: Geological map of the Afar Depression

description: <strong>Content</strong> This dataset contains a geological map of the Afar Depression (1:1’000’000), including all the associated data. This dataset includes: The map in JPEG, PDF, and GeoTIFF format The shapefiles of the map One document listing all sources used for the compilation of this map (<em>Source_Material_Afar Depression.pdf)</em> One document describing the uncertainty of the map (<em>Reliability_geol_map.pdf</em>) One dating database compiling published datings from the literature in .txt and shapefile formats. This database has been reviewed and mistakes in coordinates were corrected (see comments column). The precision of the position is also evaluated (1 = poor - possibly up to more than 10km uncertainty; 2 = average - no precise GPS measurement of the coordinates but good localisation on map or description of the outcrop; 3 = very good - most of the time GPS measurement or very precise descriptions/map). This database is an additional complement to the paper ‘Rime, V., Foubert, A., Ruch, J. & Kidane, T. (in prep.), Tectonostratigraphic evolution and significance of the Afar Depression’<em>.</em> <strong>References</strong> The map was developed by compiling a large number of published maps, descriptions, datings and other studies, complemented by fieldwork and remote sensing. All sources and references are mentioned in the <em>Source_Material_Afar_Depression</em>. Material and methods of mapping have been described in detail within the paper. <strong>Citation</strong> When using the data, please cite the data as ‘Rime, V., Foubert, A., Atnafu, B. & Kidane, T. (2022) Geological map of the Afar Depression. Zenodo’ and refer to the accompanying paper as ‘Rime, V., Foubert, A., Ruch, J. & Kidane, T. (in prep.) Tectonostratigraphic evolution and significance of the Afar Depression’ The map and additional data are given without any guarantee of correctness. Any use of these are under the user’s full responsibility. The authors decline any responsibility. <strong>Acknowledgements</strong> This study was funded by the Swiss National Science Foundation (SNF project SERENA – SEdimentary REcord of the Northern Afar 200021_163114). We are grateful to the University of Fribourg (Switzerland), the University of Addis Ababa (Ethiopia), the Ethiopian Ministry of Mines and Energy, the Ethiopian Geological Survey, Circum Minerals, former Allana Potash and Yara Dallol for their support. We particularly acknowledge Samuel Getachew that helped us to access some of the geological maps. We thank David Jaramillo-Vogel, Jean-Charles Schaegis, Haileyesus Negga, Addis Endeshaw, Ermias Gebru, Eva de Boever, Juan-Carlos Braga, Pia Wyler, Xenia Haberditz, the Ethioder team as well as the regional and local administration of the Afar for their help and support during fieldwork.
DOI: 10.5281/zenodo.7410068
title: Geological map of the Afar Depression

description: <strong>Content</strong> This dataset contains a geological map of the Afar Depression (1:1’000’000), including all the associated data. This dataset includes: The map in JPEG, PDF, and GeoTIFF format The shapefiles of the map One document listing all sources used for the compilation of this map (<em>Source_Material_Afar Depression.pdf)</em> One document describing the uncertainty of the map (<em>Reliability_geol_map.pdf</em>) One dating database compiling published datings from the literature in .txt and shapefile formats. This database has been reviewed and mistakes in coordinates were corrected (see comments column). The precision of the position is also evaluated (1 = poor - possibly up to more than 10km uncertainty; 2 = average - no precise GPS measurement of the coordinates but good localisation on map or description of the outcrop; 3 = very good - most of the time GPS measurement or very precise descriptions/map). This database is an additional complement to the paper ‘Rime, V., Foubert, A., Ruch, J. & Kidane, T. (in prep.), Tectonostratigraphic evolution and significance of the Afar Depression’<em>.</em> <strong>References</strong> The map was developed by compiling a large number of published maps, descriptions, datings and other studies, complemented by fieldwork and remote sensing. All sources and references are mentioned in the <em>Source_Material_Afar_Depression</em>. Material and methods of mapping have been described in detail within the paper. <strong>Citation</strong> When using the data, please cite the data as ‘Rime, V., Foubert, A., Atnafu, B. & Kidane, T. (2022) Geological map of the Afar Depression. Zenodo’ and refer to the accompanying paper as ‘Rime, V., Foubert, A., Ruch, J. & Kidane, T. (in prep.) Tectonostratigraphic evolution and significance of the Afar Depression’ The map and additional data are given without any guarantee of correctness. Any use of these are under the user’s full responsibility. The authors decline any responsibility. <strong>Acknowledgements</strong> This study was funded by the Swiss National Science Foundation (SNF project SERENA – SEdimentary REcord of the Northern Afar 200021_163114). We are grateful to the University of Fribourg (Switzerland), the University of Addis Ababa (Ethiopia), the Ethiopian Ministry of Mines and Energy, the Ethiopian Geological Survey, Circum Minerals, former Allana Potash and Yara Dallol for their support. We particularly acknowledge Samuel Getachew that helped us to access some of the geological maps. We thank David Jaramillo-Vogel, Jean-Charles Schaegis, Haileyesus Negga, Addis Endeshaw, Ermias Gebru, Eva de Boever, Juan-Carlos Braga, Pia Wyler, Xenia Haberditz, the Ethioder team as well as the regional and local administration of the Afar for their help and support during fieldwork.
DOI: 10.5281/zenodo.4718645
title: Metagenome assembled genome database of a human cohort and fecal reactors

description: <strong>HumanCohort_annotations.tsv.zip:</strong> This is the custom MAG database (n=2447 MAGs) and corresponding annotations that were used in Borton 2022: "Targeted curation of the gut microbial gene content modulating human cardiovascular disease". The citation will be updated upon publication of the manuscript. Metagenome assembled genomes were generated from fecal metagenomes derived from a 54 person cohort and anoxic methylated amine enrichments. <strong>HumanCohortmetabolism_summary.xlsx.zip: </strong> This is the annotation summary for 2447 MAGs in the cohort database. <strong>Quality_Abundance_CohortMAGs.xlsx: </strong>This is a genome inventory of the 2447 MAGs in the cohort database including genome statistics and relative abundance. <strong>orig_1D_NMR_fids.zip: </strong>NMR data derived from anoxic methylated amine enrichments.
DOI: 10.5281/zenodo.4718646
title: Metagenome assembled genome database of a human cohort and fecal reactors

description: This is the custom MAG database and corresponding annotations that were used in Borton 2021: "Cardiovascular disease is predicted by methylated amine metabolism encoded by the gut microbiome". The citation will be updated upon publication of the manuscript.
DOI: 10.5281/zenodo.4977712
title: Metagenome assembled genome database of a human cohort and fecal reactors

description: <strong>genome_annotations.tar.gz:</strong> This is the custom MAG database and corresponding annotations that were used in Borton 2021: "Cardiovascular disease is predicted by methylated amine metabolism encoded by the gut microbiome". The citation will be updated upon publication of the manuscript. Metagenome assembled genomes were generated from fecal metagenomes derived from a 54 person cohort and anoxic methylated amine enrichments. <strong>orig_1D_NMR_fids.zip: </strong>NMR data derived from anoxic methylated amine enrichments.
DOI: 10.5281/zenodo.7409994
title: Metagenome assembled genome database of a human cohort and fecal reactors

description: <strong>HumanCohort_annotations.tsv.zip:</strong> This is the custom MAG database (n=2447 MAGs) and corresponding annotations that were used in Borton 2022: "Targeted curation of the gut microbial gene content modulating human cardiovascular disease". The citation will be updated upon publication of the manuscript. Metagenome assembled genomes were generated from fecal metagenomes derived from a 54 person cohort and anoxic methylated amine enrichments. <strong>HumanCohortmetabolism_summary.xlsx.zip: </strong> This is the annotation summary for 2447 MAGs in the cohort database. <strong>Quality_Abundance_CohortMAGs.xlsx: </strong>This is a genome inventory of the 2447 MAGs in the cohort database including genome statistics and relative abundance. <strong>orig_1D_NMR_fids.zip: </strong>NMR data derived from anoxic methylated amine enrichments.
DOI: 10.25934/pr00005786.3
title: Available IPD datapackage for study 'A Phase III Randomized, Multicenter, Two Arm, Open-label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy'

description: This randomized, multicenter, 2-arm, open-label study (TH3RESA) will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) in comparison with treatment of the physician's choice in participants with metastatic or unresectable locally advanced/recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Eligible participants will be randomized to receive either trastuzumab emtansine 3.6 mg/kg intravenously every 21 days or treatment of the physician's choice. Participants continue to receive study treatment until disease progression or unacceptable toxicity occurs. This study is also known under Roche study protocol number BO25734.
DOI: 10.5281/zenodo.7410048
title: DS1_mT_GestInOut_v1.0

description: This dataset includes the raw touchpoints gathered from participants attended an elicitation study. The dataset includes several folders. Each folder corresponds to data gathered from each participant. The txt file in each folder contains the referents of the experiment followed by the touchpoints recorded for each response.
DOI: 10.5281/zenodo.7410047
title: DS1_mT_GestInOut_v1.0

description: This dataset includes the raw touchpoints gathered from participants attended an elicitation study. The dataset includes several folders. Each folder corresponds to data gathered from each participant. The txt file in each folder contains the referents of the experiment followed by the touchpoints recorded for each response.
DOI: 10.6084/m9.figshare.21688406
title: Supplementary Material for: Treatment of congenital hypothyroidism – impact of secular changes in levothyroxine initial dose on early growth

description: Introduction: Newborn screening of congenital hypothyroidism (CH) has enabled early treatment with levothyroxine (LT4), ensuring normal growth and development. The initial LT4 dose recommendation has increased over decades. We evaluated whether the increased LT4 dosing influenced thyroid-stimulating hormone (TSH) and thyroxine (fT4) concentrations, growth, or treatment-related symptoms. Methods: LT4 doses, TSH, fT4, anthropometrics, and treatment-related symptoms until age two years were evaluated in 172 Finnish CH patients born between 1980 and 2018. The patients were grouped according to birth decade: 1980s (n = 19, mean LT4 starting dose 6.8 µg/kg/day), 1990s (n = 50, 7.4 µg/kg/day), 2000s (n = 59, 9.7 µg/kg/day) and 2010s (n = 44, 10.8 µg/kg/day) Results: TSH concentrations were higher during the first two years of life in children born in 1980s compared to children born later. TSH concentrations were often subnormal in children receiving higher LT4 doses (children born in 2000s and 2010s). However, symptoms of overtreatment were uncommon. Linear or head growth showed no differences between the groups during the first two years of life. Although growth was within the normal spectrum, children in all groups were shorter than their target length at two years and their weight-for-length was above the mean through the first two years of life. Discussion/Conclusion: Current treatment practice with higher LT4 dose normalizes TSH rapidly without significant increase in side effects. However, irrespective of initial LT4 dose, children were shorter than expected at 2 years of age. Effects of different initial LT4 dose on cognitive development urges further investigation.
DOI: 10.6084/m9.figshare.21688406.v1
title: Supplementary Material for: Treatment of congenital hypothyroidism – impact of secular changes in levothyroxine initial dose on early growth

description: Introduction: Newborn screening of congenital hypothyroidism (CH) has enabled early treatment with levothyroxine (LT4), ensuring normal growth and development. The initial LT4 dose recommendation has increased over decades. We evaluated whether the increased LT4 dosing influenced thyroid-stimulating hormone (TSH) and thyroxine (fT4) concentrations, growth, or treatment-related symptoms. Methods: LT4 doses, TSH, fT4, anthropometrics, and treatment-related symptoms until age two years were evaluated in 172 Finnish CH patients born between 1980 and 2018. The patients were grouped according to birth decade: 1980s (n = 19, mean LT4 starting dose 6.8 µg/kg/day), 1990s (n = 50, 7.4 µg/kg/day), 2000s (n = 59, 9.7 µg/kg/day) and 2010s (n = 44, 10.8 µg/kg/day) Results: TSH concentrations were higher during the first two years of life in children born in 1980s compared to children born later. TSH concentrations were often subnormal in children receiving higher LT4 doses (children born in 2000s and 2010s). However, symptoms of overtreatment were uncommon. Linear or head growth showed no differences between the groups during the first two years of life. Although growth was within the normal spectrum, children in all groups were shorter than their target length at two years and their weight-for-length was above the mean through the first two years of life. Discussion/Conclusion: Current treatment practice with higher LT4 dose normalizes TSH rapidly without significant increase in side effects. However, irrespective of initial LT4 dose, children were shorter than expected at 2 years of age. Effects of different initial LT4 dose on cognitive development urges further investigation.
DOI: 10.5281/zenodo.7006888
title: DATASET: characterization of the seed coat extractable phenolic profile and color in 308 common bean lines of the Spanish Diversity Panel

description: Characterizarion of the seed coat extractable phenolic profile and color in 308 common bean lines of the Spanish Diversity Panel
description: This work was supported in part by I+D+I project AGL2017-87050-R financed by MCIN/AEI/10.13039/501100011033 and FEDER funds "Una manera de hacer Europa", and by the Principado de Asturias, PCTI 2021-2023 (GRUPIN:IDI/2021/000104) and FEDER funds
DOI: 10.5281/zenodo.7006887
title: DATASET: characterization of the seed coat extractable phenolic profile and color in 308 common bean lines of the Spanish Diversity Panel

description: Characterizarion of the seed coat extractable phenolic profile and color in 308 common bean lines of the Spanish Diversity Panel
description: This work was supported in part by I+D+I project AGL2017-87050-R financed by MCIN/AEI/10.13039/501100011033 and FEDER funds "Una manera de hacer Europa", and by the Principado de Asturias, PCTI 2021-2023 (GRUPIN:IDI/2021/000104) and FEDER funds
DOI: 10.5281/zenodo.7003991
title: DATASET: Genotyping by sequencing of the common bean Spanish Diversity Panel

description: Genotyping by sequencing of 308 common bean lines included in the Spanish Diversity Panel. The ApeKI restriction enzyme was used. The sequencing reads were aligned using the reference genome V2.1 (https://phytozome.jgi.doe.gov/pz/portal.html#!info?alias=Org_Pvulgaris). A total of 11,763 SNP markers are included in this dataset after filtering for missing values (&lt; 10%) and minor allele frequency (MAF&gt; 0.05).
description: This work was supported the I+D+I project AGL2017-87050-R financed by MCIN/AEI/10.13039/501100011033 (Spain) and FEDER funds "Una manera de hacer Europa"